Mizuho increased its price target for Gilead Sciences (GILD) from $131 to $140, maintaining an Outperform rating due to a stronger Biktarvy timeline, with market exclusivity now expected until 2036. This positive outlook is tempered by the failure of Gilead's Trodelvy in a Phase 3 trial for metastatic breast cancer, though potential in the pre-exposure prophylaxis market for Yeztugo is noted.

吉利德科學

<p>瑞穗證券將吉利德科學（GILD）的目標股價從 131 美元上調至 140 美元，維持 “跑贏大盤” 評級，原因是 Biktarvy 的時間表更為強勁，市場獨佔期預計將持續至 2036 年。然而，吉利德的 Trodelvy 在轉移性乳腺癌的三期試驗中失敗，這一積極展望受到一定影響，但 Yeztugo 在暴露前預防市場的潛力仍然受到關注</p>

吉利德科學（GILD）股票展望：瑞穗銀行因 Biktarvy 時間線的增強而提高目標價